JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
Krämer
Alwin
A
Department of Internal Medicine V, University of Heidelberg, Heidelberg Germany. a.kraemer@dkfz-heidelberg.de
Reiter
Andreas
A
Kruth
Jens
J
Erben
Philipp
P
Hochhaus
Andreas
A
Müller
Martin
M
Cross
Nicholas C P
NC
Jones
Amy V
AV
Ho
Anthony D
AD
Hensel
Manfred
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002869:Chromosome Aberrations; D002908:Chronic Disease; D004252:DNA Mutational Analysis; D016313:Genes, abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C507924:JAK2 protein, human; D053614:Janus Kinase 2